Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M7,084Revenue (TTM) $M250Net Margin (%)-42.1Altman Z-Score3.8
Enterprise Value $M6,979EPS (TTM) $-0.7Operating Margin %-27.1Piotroski F-Score6
P/E(ttm)--Beneish M-Score-3.1Pre-tax Margin (%)-41.7Higher ROA y-yY
Price/Book83.610-y EBITDA Growth Rate %--Quick Ratio4.0Cash flow > EarningsY
Price/Sales28.65-y EBITDA Growth Rate %-25.3Current Ratio4.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-20.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-344.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M157ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with NKTR

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

NKTR is held by these investors:



NKTR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Nicholson JohnSVP & COO 2017-11-13Sell15,910$37.7818.93view
Doberstein Stephen KSVP & Chief Scientific Officer 2017-11-08Sell396,323$2954.93view
Hora ManinderSVP Pharma Dev & Mfg Ops 2017-11-06Sell5,117$25.0779.22view
ROBIN HOWARD WPresident & CEO 2017-11-01Sell83,334$23.5790.62view
ROBIN HOWARD WPresident & CEO 2017-10-09Sell83,333$24.285.66view
Hora ManinderSVP Pharma Dev & Mfg Ops 2017-10-05Sell7,583$2579.72view
Doberstein Stephen KSVP & Chief Scientific Officer 2017-10-05Sell43,677$24.9779.94view
Gergel Ivan P.SVP & Chief Medical Officer 2017-10-02Sell100,000$24.1486.12view
Labrucherie Gil MSVP & CFO 2017-10-02Sell120,000$24.4583.76view
Lingnau LutzDirector 2017-09-22Sell5,000$21.97104.51view

Quarterly/Annual Reports about NKTR:

News about NKTR:

Articles On GuruFocus.com
First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma Nov 11 2017 
Largest Insider Trades of the Week Nov 10 2017 
Nektar to Webcast Presentation at Jefferies 2017 London Healthcare Conference Nov 10 2017 
Factors of Influence in 2018, Key Indicators and Opportunity within Tegna, Inpixon, Honeywell Intern Nov 09 2017 
New Data Featuring Nektar Therapeutics' Wholly-Owned Immuno-Oncology Pipeline to be Presented at the Nov 07 2017 
Nektar Therapeutics Presents Preclinical Data on NKTR-358, a First-in-Class Regulatory T Cell Stimul Nov 07 2017 
Nektar to Announce Financial Results for the Third Quarter of 2017 on Tuesday, November 7, 2017, Aft Oct 31 2017 
Nektar Therapeutics Appoints Biotechnology Executive Jeff Ajer as New Board Member Sep 21 2017 
Nektar Therapeutics Announces Seven Abstracts Accepted for Presentation at 2017 Society for Immunoth Sep 20 2017 
Nektar Therapeutics Initiates PROPEL Clinical Study to Evaluate Combination of NKTR-214, a CD122-Bia Sep 12 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK